Improvement in glycaemic control and reduction in body weight over 52 weeks with dapagliflozin as add-on therapy to metformin plus sulphonylurea

被引：0
|
作者：
Matthaei, S. [1 ]
Bowering, K. [2 ]
Rohwedder, K. [3 ]
Grohl, A. [4 ]
Johnsson, E. [5 ]
机构：
[1] Diabet Zentrum Quakenbruck, Berlin, Germany
[2] Univ Alberta, Edmonton, AB, Canada
[3] AstraZeneca, Wedel, Germany
[4] Aptiv Solut, Cologne, Germany
[5] AstraZeneca, Molndal, Sweden
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
852
引用
收藏
页码：S347 / S347
页数：1
相关论文
共 50 条
  • [31] POSTPRANDIAL DYNAMICS OF PLASMA GLUCOSE, INSULIN, AND GLUCAGON IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN ADD-ON TO METFORMIN THERAPY
    Hansen, Lars
    Iqbal, Nayyar
    Ekholm, Ella
    Cook, William
    Hirshberg, Boaz
    ENDOCRINE PRACTICE, 2014, 20 (11) : 1187 - 1197
  • [32] ADD-ON THERAPY WITH DAPAGLIFLOZIN IMPROVES FULL CLOSED LOOP POST PRANDIAL GLYCAEMIC CONTROL IN TYPE 1 DIABETIC YOUNG ADULTS - THE DAPADREAM
    Biester, T.
    Nieswandt, A.
    Biester, S.
    Remus, K.
    Dovc, K.
    Bratina, N.
    Scheerer, M.
    Nimri, R.
    Muller, I.
    Atlas, E.
    Battelino, T.
    Phillip, M.
    Kordonouri, O.
    Danne, T.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A11 - A12
  • [33] Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
    Nauck, M. A.
    Del Prato, S.
    Duran-Garcia, S.
    Rohwedder, K.
    Langkilde, A. M.
    Sugg, J.
    Parikh, S. J.
    DIABETES OBESITY & METABOLISM, 2014, 16 (11): : 1111 - 1120
  • [34] Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
    Rosenstock, Julio
    Hansen, Lars
    Zee, Pamela
    Li, Yan
    Cook, William
    Hirshberg, Boaz
    Iqbal, Nayyar
    DIABETES CARE, 2015, 38 (03) : 376 - 383
  • [35] Long-term efficacy and safety of evogliptin add-on therapy to dapagliflozin plus metformin combinations in poorly controlled patients with type 2 diabetes
    Moon, J.
    Kim, H.
    Chung, C.
    Won, K.
    Han, K.
    Park, C.
    Won, J.
    Kim, D.
    Koh, G.
    Kim, E.
    Yu, J.
    Hong, E.
    Lee, C.
    Yoon, K.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S307 - S307
  • [36] Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial
    Vilsboll, Tina
    Ekholm, Ella
    Johnsson, Eva
    Dronamraju, Nalina
    Jabbour, Serge
    Lind, Marcus
    DIABETES CARE, 2019, 42 (08) : 1464 - 1472
  • [37] Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
    Ratner, R. E.
    Maggs, D.
    Nielsen, L. L.
    Stonehouse, A. H.
    Poon, T.
    Zhang, B.
    Bicsak, T. A.
    Brodows, R. G.
    Kim, D. D.
    DIABETES OBESITY & METABOLISM, 2006, 8 (04): : 419 - 428
  • [38] Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes
    Nauck, MA
    Hompesch, M
    Filipczak, R
    Le, TDT
    Nielsen, L
    Zdravkovic, M
    Gumprecht, J
    DIABETES, 2004, 53 : A83 - A83
  • [39] Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
    Bolinder, J.
    Ljunggren, O.
    Johansson, L.
    Wilding, J.
    Langkilde, A. M.
    Sjostrom, C. D.
    Sugg, J.
    Parikh, S.
    DIABETES OBESITY & METABOLISM, 2014, 16 (02): : 159 - 169
  • [40] Empagliflozin as add-on to basal insulin for 78 weeks improves glycaemic control with weight loss in insulin-treated type 2 diabetes mellitus
    Rosenstock, J.
    Jelaska, A.
    Wang, F.
    Kim, G.
    Broedl, U. C.
    Woerle, H. J.
    DIABETOLOGIA, 2013, 56 : S372 - S372
12345